Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.33 Analyst target: $7.12 Upside: 435.34%
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. The company is headquartered in Los Altos, California.
See the full interactive analysis & chart →Informational only — not investment advice.